136 studies found for:    "Adenocarcinoma of the appendix"
Show Display Options
Rank Status Study
21 Active, not recruiting TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: TLR8 agonist VTX-2337;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: paclitaxel
22 Recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Procedure: mesenchymal stem cell transplantation;   Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis
23 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: cisplatin;   Other: quality-of-life assessment
24 Recruiting EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
25 Active, not recruiting Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: carboplatin;   Biological: bevacizumab;   Other: laboratory biomarker analysis
26 Not yet recruiting Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: metformin hydrochloride;   Drug: placebo;   Other: laboratory biomarker analysis
27 Recruiting Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: panitumumab;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Drug: leucovorin calcium
28 Terminated Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Conditions: Liver Metastases;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Device: irinotecan-eluting beads;   Procedure: hepatic artery embolization
29 Withdrawn Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage I Colon Cancer;   Stage I Rectal Cancer
Interventions: Dietary Supplement: cholecalciferol;   Procedure: biopsy;   Genetic: protein expression analysis;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Genetic: reverse transcriptase-polymerase chain reaction
30 Completed A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Biological: bevacizumab
31 Recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Cannot Removed by Surgery
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
32 Terminated Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Biological: cetuximab;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
33 Completed Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Procedure: quality-of-life assessment
34 Recruiting Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride;   Drug: alisertib
35 Not yet recruiting Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
Conditions: Liver Metastases;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Device: irinotecan-eluting beads;   Procedure: hepatic artery embolization
36 Terminated
Has Results
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
Conditions: Liver Metastases;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: cetuximab;   Drug: dasatinib;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
37 Recruiting Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis;   Other: questionnaire administration
38 Terminated Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: gefitinib;   Drug: leucovorin calcium;   Drug: fluorouracil
39 Terminated Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: fluorouracil;   Drug: sodium phenylbutyrate;   Drug: indomethacin;   Biological: recombinant interferon gamma
40 Recruiting Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: aflibercept;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil;   Other: Correlative Studies;   Procedure: DCE MRI;   Radiation: f18FDG-PET;   Procedure: PET (positron emission tomography)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years